-
公开(公告)号：US20220249487A1
公开(公告)日：2022-08-11
申请号：US17643623
申请日：2021-12-10
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Georgette Castanedo , Paul Gibbons , Joachim Rudolph , Yao Wu , Guosheng Wu
IPC: A61K31/517 , C07D401/12 , C07D239/84 , C07D401/04 , C07D401/14 , A61K31/573 , A61K38/07 , A61K31/69 , A61K31/454 , A61K39/395 , C07D405/14
Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.
-
公开(公告)号：US11236046B2
公开(公告)日：2022-02-01
申请号：US16657102
申请日：2019-10-18
Applicant: Genentech, Inc.
Inventor： Huifen Chen , Yanyan Chu , Steven Do , Anthony Estrada , Baihua Hu , Aleksandr Kolesnikov , Xingyu Lin , Joseph P. Lyssikatos , Daniel Shore , Vishal Verma , Lan Wang , Guosheng Wu , Po-wai Yuen
IPC: C07D207/48 , C07D403/12 , C07D401/14 , C07D401/12 , C07D403/14 , C07D417/12 , C07D451/02 , C07D491/048 , C07D405/14
Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
-
公开(公告)号：US20180327420A1
公开(公告)日：2018-11-15
申请号：US16044862
申请日：2018-07-25
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Keira Garland , Emily Hanan , Hans Purkey , Steven T. Staben , Robert Andrew Heald , Jamie Knight , Calum Macleod , Aijun Lu , Guosheng Wu , Siew Kuen Yeap
IPC: C07D498/04 , C07D519/00 , C07D498/06 , A61K31/5365 , A61K31/4188 , A61K31/498 , A61K31/4196 , C07D491/044 , A61K31/428 , A61K31/4439 , A61K31/5383 , A61K31/553 , A61K45/06 , A61K31/423
CPC classification number: C07D498/04 , A61K31/4188 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/498 , A61K31/5365 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D491/044 , C07D498/06 , C07D519/00
Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
公开(公告)号：US20180244694A1
公开(公告)日：2018-08-30
申请号：US15962333
申请日：2018-04-25
Applicant: Genentech, Inc.
Inventor： Yu Jiang , Guosheng Wu , Po-Wai Yuen , Elisia Villemure , Jacob Schwarz , Cuong Ly , Benjamin Sellers , Matthew Volgraf
IPC: C07D513/14 , C07D519/00 , C07D513/04 , C07D513/10
CPC classification number: C07D513/14 , C07D513/04 , C07D513/10 , C07D519/00
Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
-
公开(公告)号：US20180118680A1
公开(公告)日：2018-05-03
申请号：US15851322
申请日：2017-12-21
Applicant: Genentech, Inc.
Inventor： Huifen Chen , Yanyan Chu , Steven Do , Anthony Estrada , Baihua Hu , Aleksandr Kolesnikov , Xingyu Lin , Joseph P. Lyssikatos , Daniel Shore , Vishal Verma , Lan Wang , Guosheng Wu , Po-wai Yuen
IPC: C07D207/48 , C07D403/14 , C07D417/12 , C07D403/12 , C07D451/02 , C07D405/14 , C07D401/14 , C07D491/048 , C07D401/12
Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
-
Patent Agency Ranking
公开(公告)号：US20160200739A1
公开(公告)日：2016-07-14
申请号：US15074100
申请日：2016-03-18
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D401/14 , C07D413/14 , C07D471/04 , C07D413/10 , C07D401/10 , C07D403/10 , C07D491/052
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20220306635A1
公开(公告)日：2022-09-29
申请号：US17068574
申请日：2020-10-12
Applicant: Genentech, Inc. , NewLink Genetics Corporation
Inventor： Xingyu Lin , Po-wai Yuen , Rohan Mendonca , Brendan Parr , Richard Pastor , Zhonghua Pei , Lewis Gazzard , Firoz Jaipuri , Sanjeev Kumar , Xiaokai Li , Roheeth Pavana , Hima Potturi , Venkata Velvadapu , Jesse Waldo , Zuhui Zhang , Guosheng Wu , Benjamin Douglas Sellers
IPC: C07D487/04 , A61P35/00 , A61K38/16 , A61K45/06 , C07D519/00
Abstract: Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
-
公开(公告)号：US10647731B2
公开(公告)日：2020-05-12
申请号：US15962333
申请日：2018-04-25
Applicant: Genentech, Inc.
Inventor： Yu Jiang , Guosheng Wu , Po-Wai Yuen , Elisia Villemure , Jacob Schwarz , Cuong Ly , Benjamin Sellers , Matthew Volgraf
IPC: C07D513/14 , C07D513/04 , C07D513/10 , C07D519/00
Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
-
公开(公告)号：US20190016726A1
公开(公告)日：2019-01-17
申请号：US16065397
申请日：2016-12-23
Applicant: Genentech, Inc. , NewLink Genetics Corporation
Inventor： Xingyu Lin , Po-wai Yuen , Rohan Mendonca , Brendan Parr , Richard Pastor , Zhonghua Pei , Lewis Gazzard , Firoz Jaipuri , Sanjeev Kumar , Xiaokai Li , Roheeth Pavana , Hima Potturi , Venkata Velvadapu , Jesse Waldo , Zuhui Zhang , Guosheng Wu
IPC: C07D487/04 , A61P35/00 , C07D519/00 , A61K38/16
Abstract: Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
-
公开(公告)号：US20180065983A1
公开(公告)日：2018-03-08
申请号：US15258175
申请日：2016-09-07
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Keira Garland , Emily Hanan , Hans Purkey , Steven T. Staben , Robert Andrew Heald , Jamie Knight , Calum Macleod , Aijun Lu , Guosheng Wu , Siew Kuen Yeap
IPC: C07D498/04 , A61K31/553 , A61K31/5383 , A61K31/498 , A61K31/4439 , A61K31/428 , A61K31/423 , A61K31/4196 , C07D491/044 , A61K45/06 , C07D519/00
CPC classification number: C07D498/04 , A61K31/4188 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/498 , A61K31/5365 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D491/044 , C07D498/06 , C07D519/00
Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.044 seconds)
